Selection of recent multicenter national and international consortia and collaboration efforts in BPDCN
| Consortium/group . | Countries represented . | Reference . |
|---|---|---|
| North American Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Consortium (NABC) | USA, Canada, Mexico | Pemmaraju et al, Blood 2023 |
| Ad Hoc International Expert Panel: Consensus Guidelines | Italy, Netherlands, Spain, USA | Pagano et al, HemaSphere 2023 |
| BPDCN Pediatric/AYA US Group | USA | Cuglievan et al, Leukemia 2023 |
| BPDCN International Registry | Armenia, Canada, Cyprus, Egypt, Georgia, India, Italy, Taiwan, Turkey, UK, and USA; Egypt, Iraq, Canada, Netherlands, Tajikistan, Czech Republic, Guatemala, Brazil, Serbia, Germany | Voskanyan and Tamamyan et al, ASH 2023 |
| China Knowledge Network database: BPDCN outcomes analysis | China | Gong et al 2024 |
| NCCN Clinical Practice Guidelines in Oncology: AML, version 3.2023: BPDCN guidelines | USA | Pollyea 2023 |
| CIBMTR analysis: allogeneic stem cell transplantation in BPDCN | USA, Canada, Saudi Arabia, Japan, Switzerland, Spain, France, UAE, Netherlands | Murthy et al, Blood Advances 2023 |
| French BPDCN Network | France | Garnache-Ottou et al, Blood Advances 2019 |
| Hematopathology/Dermatopathology Multicenter Working Group | USA | Ohgami et al, Arch Pathol Lab Med 2023 |
| Multicenter analysis of outcomes in BPDCN | USA | Taylor et al, Blood 2019 |
| Divergent clonal evolution of BPDCN and CMML from shared TET2-mutated origin | UK and USA | Batta and Wiseman, Leukemia 2021 |
| Social Media in #BPDCN | USA and Canada | Pemmaraju et al, Curr Hematol Malig Rep 2018 |
| Sex-biased ZRSR2 mutations in BPDCN | USA, Singapore, France, Italy | Togami and Lane, Cancer Discovery 2022 |
| Consortium/group . | Countries represented . | Reference . |
|---|---|---|
| North American Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Consortium (NABC) | USA, Canada, Mexico | Pemmaraju et al, Blood 2023 |
| Ad Hoc International Expert Panel: Consensus Guidelines | Italy, Netherlands, Spain, USA | Pagano et al, HemaSphere 2023 |
| BPDCN Pediatric/AYA US Group | USA | Cuglievan et al, Leukemia 2023 |
| BPDCN International Registry | Armenia, Canada, Cyprus, Egypt, Georgia, India, Italy, Taiwan, Turkey, UK, and USA; Egypt, Iraq, Canada, Netherlands, Tajikistan, Czech Republic, Guatemala, Brazil, Serbia, Germany | Voskanyan and Tamamyan et al, ASH 2023 |
| China Knowledge Network database: BPDCN outcomes analysis | China | Gong et al 2024 |
| NCCN Clinical Practice Guidelines in Oncology: AML, version 3.2023: BPDCN guidelines | USA | Pollyea 2023 |
| CIBMTR analysis: allogeneic stem cell transplantation in BPDCN | USA, Canada, Saudi Arabia, Japan, Switzerland, Spain, France, UAE, Netherlands | Murthy et al, Blood Advances 2023 |
| French BPDCN Network | France | Garnache-Ottou et al, Blood Advances 2019 |
| Hematopathology/Dermatopathology Multicenter Working Group | USA | Ohgami et al, Arch Pathol Lab Med 2023 |
| Multicenter analysis of outcomes in BPDCN | USA | Taylor et al, Blood 2019 |
| Divergent clonal evolution of BPDCN and CMML from shared TET2-mutated origin | UK and USA | Batta and Wiseman, Leukemia 2021 |
| Social Media in #BPDCN | USA and Canada | Pemmaraju et al, Curr Hematol Malig Rep 2018 |
| Sex-biased ZRSR2 mutations in BPDCN | USA, Singapore, France, Italy | Togami and Lane, Cancer Discovery 2022 |